Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.

Raymond E, Chong E, Winikoff B, Platais I, Mary M, Lotarevich T, Castillo PW, Kaneshiro B, Tschann M, Fontanilla T, Baldwin M, Schnyer A, Coplon L, Mathieu N, Bednarek P, Keady M, Priegue E.

Contraception. 2019 Jun 4. pii: S0010-7824(19)30176-3. doi: 10.1016/j.contraception.2019.05.013. [Epub ahead of print]

PMID:
31170384
2.

A prospective study of mifepristone and unlimited dosing of sublingual misoprostol for termination of second-trimester pregnancy in Uzbekistan and Ukraine.

Platais I, Tsereteli T, Maystruk G, Kurbanbekova D, Winikoff B.

BMJ Sex Reprod Health. 2019 Jun 4. pii: bmjsrh-2018-200167. doi: 10.1136/bmjsrh-2018-200167. [Epub ahead of print]

PMID:
31164394
3.

Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee.

Mark A, Foster AM, Grossman D, Prager SW, Reeves M, Velásquez CV, Winikoff B.

Contraception. 2019 May;99(5):265-266. doi: 10.1016/j.contraception.2019.02.008. Epub 2019 Mar 10. No abstract available.

PMID:
30867121
4.

Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.

Sheldon WR, Durocher J, Dzuba IG, Sayette H, Martin R, Velasco MC, Winikoff B.

Contraception. 2019 May;99(5):272-277. doi: 10.1016/j.contraception.2019.02.002. Epub 2019 Mar 1.

PMID:
30831103
5.

Intramuscular injection, intravenous infusion, and intravenous bolus of oxytocin in the third stage of labor for prevention of postpartum hemorrhage: a three-arm randomized control trial.

Charles D, Anger H, Dabash R, Darwish E, Ramadan MC, Mansy A, Salem Y, Dzuba IG, Byrne ME, Breebaart M, Winikoff B.

BMC Pregnancy Childbirth. 2019 Jan 18;19(1):38. doi: 10.1186/s12884-019-2181-2.

6.

Could second-trimester medical abortion be offered as a day service? Assessing the feasibility of a 1-day outpatient procedure using pooled data from six clinical studies.

Shochet T, Dragoman M, Blum J, Abbas D, Louie K, Platais I, Tsereteli T, Winikoff B.

Contraception. 2019 May;99(5):288-292. doi: 10.1016/j.contraception.2018.12.004. Epub 2019 Jan 10.

PMID:
30639446
7.

Using misoprostol to treat postpartum hemorrhage in home deliveries attended by traditional birth attendants.

Abbas DF, Jehan N, Diop A, Durocher J, Byrne ME, Zuberi N, Ahmed Z, Walraven G, Winikoff B.

Int J Gynaecol Obstet. 2019 Mar;144(3):290-296. doi: 10.1002/ijgo.12756. Epub 2019 Jan 24.

PMID:
30582753
8.

Use of an at-home multilevel pregnancy test and an automated call-in system to follow-up the outcome of medical abortion.

Anger H, Dabash R, Peña M, Coutiño D, Bousiéguez M, Sanhueza P, Winikoff B.

Int J Gynaecol Obstet. 2019 Jan;144(1):97-102. doi: 10.1002/ijgo.12679. Epub 2018 Oct 8.

PMID:
30221366
9.

Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore.

Tan YL, Singh K, Tan KH, Gosavi A, Koh D, Abbas D, Winikoff B.

Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:144-147. doi: 10.1016/j.ejogrb.2018.08.014. Epub 2018 Aug 28.

PMID:
30179732
10.

A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion.

Easterling T, Hebert M, Bracken H, Darwish E, Ramadan MC, Shaarawy S, Charles D, Abdel-Aziz T, Nasr AS, Safwal SM, Winikoff B.

BMC Pregnancy Childbirth. 2018 Jul 6;18(1):290. doi: 10.1186/s12884-018-1919-6.

11.

Foley catheter vs. oral misoprostol to induce labour among hypertensive women in India: a cost-consequence analysis alongside a clinical trial.

Leigh S, Granby P, Haycox A, Mundle S, Bracken H, Khedikar V, Mulik J, Faragher B, Easterling T, Turner MA, Alfirevic Z, Winikoff B, Weeks AD.

BJOG. 2018 Dec;125(13):1734-1742. doi: 10.1111/1471-0528.15285. Epub 2018 Jun 22.

12.

Postpartum hemorrhage: new insights for definition and diagnosis.

Borovac-Pinheiro A, Pacagnella RC, Cecatti JG, Miller S, El Ayadi AM, Souza JP, Durocher J, Blumenthal PD, Winikoff B.

Am J Obstet Gynecol. 2018 Aug;219(2):162-168. doi: 10.1016/j.ajog.2018.04.013. Epub 2018 Apr 14.

PMID:
29660298
13.

Simplified medical abortion screening: a demonstration project.

Raymond EG, Tan YL, Comendant R, Sagaidac I, Hodorogea S, Grant M, Sanhueza P, Van Pratt E, Gillespie G, Boraas C, Weaver MA, Platais I, Bousieguez M, Winikoff B.

Contraception. 2018 Apr;97(4):292-296. doi: 10.1016/j.contraception.2017.11.005. Epub 2017 Nov 21.

PMID:
29170088
14.

Achieving community-based postpartum follow up in eastern Uganda: the field experience from the MamaMiso Study on antenatal distribution of misoprostol.

Ditai J, Frye LJ, Durocher J, Byrne ME, Ononge S, Winikoff B, Weeks AD.

BMC Res Notes. 2017 Oct 26;10(1):516. doi: 10.1186/s13104-017-2849-5.

15.

Exploring the feasibility of obtaining mifepristone and misoprostol from the internet.

Murtagh C, Wells E, Raymond EG, Coeytaux F, Winikoff B.

Contraception. 2018 Apr;97(4):287-291. doi: 10.1016/j.contraception.2017.09.016. Epub 2017 Oct 11.

16.

Results of a pilot study in the U.S. and Vietnam to assess the utility and acceptability of a multi-level pregnancy test (MLPT) for home monitoring of hCG trends after assisted reproduction.

Shochet T, Comstock IA, Ngoc NTN, Westphal LM, Sheldon WR, Loc LT, Blum J, Winikoff B, Blumenthal PD.

BMC Womens Health. 2017 Aug 22;17(1):67. doi: 10.1186/s12905-017-0422-y.

17.

Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial.

Mundle S, Bracken H, Khedikar V, Mulik J, Faragher B, Easterling T, Leigh S, Granby P, Haycox A, Turner MA, Alfirevic Z, Winikoff B, Weeks AD.

Lancet. 2017 Aug 12;390(10095):669-680. doi: 10.1016/S0140-6736(17)31367-3. Epub 2017 Jun 28.

PMID:
28668289
18.

FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics.

Morris JL, Winikoff B, Dabash R, Weeks A, Faundes A, Gemzell-Danielsson K, Kapp N, Castleman L, Kim C, Ho PC, Visser GHA.

Int J Gynaecol Obstet. 2017 Sep;138(3):363-366. doi: 10.1002/ijgo.12181. Epub 2017 Jun 23. No abstract available.

19.

Postpartum hemorrhage prevention in Nepal: a program assessment.

Rajbhandari SP, Aryal K, Sheldon WR, Ban B, Upreti SR, Regmi K, Aryal S, Winikoff B.

BMC Pregnancy Childbirth. 2017 Jun 5;17(1):169. doi: 10.1186/s12884-017-1347-z.

20.

Sixteen Years of Overregulation: Time to Unburden Mifeprex.

Mifeprex REMS Study Group, Raymond EG, Blanchard K, Blumenthal PD, Cleland K, Foster AM, Gold M, Grossman D, Pendergast MK, Westhoff CL, Winikoff B.

N Engl J Med. 2017 Feb 23;376(8):790-794. doi: 10.1056/NEJMsb1612526. No abstract available.

PMID:
28225670
21.

Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating and implementing a core outcome set for medical and surgical abortion.

Whitehouse KC, Kim CR, Ganatra B, Duffy JMN, Blum J, Brahmi D, Creinin MD, DePiñeres T, Gemzell-Danielsson K, Grossman D, Winikoff B, Gülmezoglu AM.

Contraception. 2017 May;95(5):437-441. doi: 10.1016/j.contraception.2016.12.009. Epub 2017 Jan 5. No abstract available.

22.

Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis.

Raymond EG, Shochet T, Blum J, Sheldon WR, Platais I, Bracken H, Dabash R, Weaver MA, Ngoc NTN, Blumenthal PD, Winikoff B.

Contraception. 2017 May;95(5):442-448. doi: 10.1016/j.contraception.2016.12.004. Epub 2016 Dec 29.

PMID:
28041991
23.

Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia.

Louie KS, Chong E, Tsereteli T, Avagyan G, Abrahamyan R, Winikoff B.

Eur J Contracept Reprod Health Care. 2017 Feb;22(1):76-80. doi: 10.1080/13625187.2016.1258461. Epub 2016 Nov 21.

PMID:
27871191
24.

Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial.

Abbas DF, Blum J, Ngoc NT, Nga NT, Chi HT, Martin R, Winikoff B.

Obstet Gynecol. 2016 Nov;128(5):1077-1083.

PMID:
27741182
25.

Profound Hyperthermia After Postpartum Rectal Misoprostol Administration.

Durocher J, Frye LJ, Winikoff B.

Obstet Gynecol. 2016 Oct;128(4):908. doi: 10.1097/AOG.0000000000001659. No abstract available.

PMID:
27661626
26.

Neither vaginal nor buccal administration of 800 μg misoprostol alters mucosal and systemic immune activation or the cervicovaginal microbiome: a pilot study.

Kalams SA, Rogers LM, Smith RM, Barnett L, Crumbo K, Sumner S, Prashad N, Rybczyk K, Milne G, Dowd SE, Chong E, Winikoff B, Aronoff DM.

Eur J Contracept Reprod Health Care. 2016 Dec;21(6):436-442. Epub 2016 Sep 16.

27.

Effects of Depot Medroxyprogesterone Acetate Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial.

Raymond EG, Weaver MA, Louie KS, Tan YL, Bousiéguez M, Aranguré-Peraza AG, Lugo-Hernández EM, Sanhueza P, Goldberg AB, Culwell KR, Kaplan C, Memmel L, Sonalkar S, Jamshidi R, Winikoff B.

Obstet Gynecol. 2016 Oct;128(4):739-45. doi: 10.1097/AOG.0000000000001627.

PMID:
27607859
28.

Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia.

Dabash R, Shochet T, Hajri S, Chelli H, Hassairi AE, Haleb D, Labassi H, Sfar E, Temimi F, Koenig L, Winikoff B.

BMC Womens Health. 2016 Jul 30;16:49. doi: 10.1186/s12905-016-0327-1.

29.

Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.

Tsereteli T, Chong E, Louie K, Bokhua Z, Winikoff B.

Eur J Contracept Reprod Health Care. 2016 Oct;21(5):367-71. doi: 10.1080/13625187.2016.1211632. Epub 2016 Jul 22.

PMID:
27449873
30.

Postpartum haemorrhage: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Kerr R, Eckert LO, Winikoff B, Durocher J, Meher S, Fawcus S, Mundle S, Mol B, Arulkumaran S, Khan K, Wandwabwa J, Kochhar S, Weeks A; Brighton Collaboration Primary Postpartum Haemorrhage Working Group.

Vaccine. 2016 Dec 1;34(49):6102-6109. doi: 10.1016/j.vaccine.2016.03.039. Epub 2016 Jul 16. No abstract available.

31.

Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks of pregnancy in Kazakhstan.

Platais I, Tsereteli T, Grebennikova G, Lotarevich T, Winikoff B.

Int J Gynaecol Obstet. 2016 Sep;134(3):268-71. doi: 10.1016/j.ijgo.2016.02.018. Epub 2016 May 26.

PMID:
27352735
32.

Medical Abortion.

Costescu D, Guilbert E, Bernardin J, Black A, Dunn S, Fitzsimmons B, Norman WV, Pymar H, Soon J, Trouton K, Wagner MS, Wiebe E, Gold K, Murray MÈ, Winikoff B, Reeves M; Society of Obstetricians and Gynecologists of Canada.

J Obstet Gynaecol Can. 2016 Apr;38(4):366-89. doi: 10.1016/j.jogc.2016.01.002. Epub 2016 Apr 23. English, French. Erratum in: J Obstet Gynaecol Can. 2017 Jan;39(1):67.

PMID:
27208607
33.

A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes.

Frye LJ, Byrne ME, Winikoff B.

Eur J Contracept Reprod Health Care. 2016 Aug;21(4):265-8. doi: 10.3109/13625187.2016.1168799. Epub 2016 Apr 22.

PMID:
27102981
34.

Randomized trial assessing home use of two pregnancy tests for determining early medical abortion outcomes at 3, 7 and 14days after mifepristone.

Blum J, Sheldon WR, Ngoc NT, Winikoff B, Nga NT, Martin R, Van Thanh L, Blumenthal PD.

Contraception. 2016 Aug;94(2):115-21. doi: 10.1016/j.contraception.2016.04.001. Epub 2016 Apr 8.

35.

Vaginal and Rectal Clostridium sordellii and Clostridium perfringens Presence Among Women in the United States.

Chong E, Winikoff B, Charles D, Agnew K, Prentice JL, Limbago BM, Platais I, Louie K, Jones HE, Shannon C; NCT01283828 Study Team.

Obstet Gynecol. 2016 Feb;127(2):360-8. doi: 10.1097/AOG.0000000000001239.

36.

Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial.

Raymond EG, Weaver MA, Tan YL, Louie KS, Bousiéguez M, Lugo-Hernández EM, Aranguré-Peraza AG, Sanhueza P, Kaplan C, Sonalkar S, Goldberg AB, Culwell KR, Memmel L, Jamshidi R, Winikoff B.

Obstet Gynecol. 2016 Feb;127(2):306-12. doi: 10.1097/AOG.0000000000001274.

PMID:
26942358
37.

Oxytocin via Uniject (a prefilled single-use injection) versus oral misoprostol for prevention of postpartum haemorrhage at the community level: a cluster-randomised controlled trial.

Diop A, Daff B, Sow M, Blum J, Diagne M, Sloan NL, Winikoff B.

Lancet Glob Health. 2016 Jan;4(1):e37-44. doi: 10.1016/S2214-109X(15)00219-3.

38.

Comment on "Is It Safe to Provide Abortion Pills Over The Counter? A Study on Outcome Following Self-Medication with Abortion Pills".

Frye LJ, Winikoff B.

J Clin Diagn Res. 2015 Aug;9(8):QL01-2. doi: 10.7860/JCDR/2015/14291.6380. Epub 2015 Aug 1. No abstract available.

39.

The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in rural Uganda: a community-based, placebo-controlled randomised trial.

Weeks AD, Ditai J, Ononge S, Faragher B, Frye LJ, Durocher J, Mirembe FM, Byamugisha J, Winikoff B, Alfirevic Z.

BMC Pregnancy Childbirth. 2015 Sep 14;15:219. doi: 10.1186/s12884-015-0650-9.

40.

Misoprostol for primary versus secondary prevention of postpartum haemorrhage: a cluster-randomised non-inferiority community trial.

Raghavan S, Geller S, Miller S, Goudar SS, Anger H, Yadavannavar MC, Dabash R, Bidri SR, Gudadinni MR, Udgiri R, Koch AR, Bellad MB, Winikoff B.

BJOG. 2016 Jan;123(1):120-7. doi: 10.1111/1471-0528.13540. Epub 2015 Sep 1.

41.

Cervical Preparation Before Dilation and Evacuation Using Adjunctive Misoprostol or Mifepristone Compared With Overnight Osmotic Dilators Alone: A Randomized Controlled Trial.

Goldberg AB, Fortin JA, Drey EA, Dean G, Lichtenberg ES, Bednarek PH, Chen BA, Dutton C, McKetta S, Maurer R, Winikoff B, Fitzmaurice GM.

Obstet Gynecol. 2015 Sep;126(3):599-609. doi: 10.1097/AOG.0000000000000977.

PMID:
26196084
42.

A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S.

Chong E, Frye LJ, Castle J, Dean G, Kuehl L, Winikoff B.

Contraception. 2015 Sep;92(3):215-9. doi: 10.1016/j.contraception.2015.06.026. Epub 2015 Jul 2.

PMID:
26142620
43.

Fifteen years: looking back and looking forward.

Winikoff B, Westhoff C.

Contraception. 2015 Sep;92(3):177-8. doi: 10.1016/j.contraception.2015.06.019. Epub 2015 Jul 2. No abstract available.

PMID:
26142617
44.

Reaching women where they are: eliminating the initial in-person medical abortion visit.

Raymond EG, Grossman D, Wiebe E, Winikoff B.

Contraception. 2015 Sep;92(3):190-3. doi: 10.1016/j.contraception.2015.06.020. Epub 2015 Jun 29.

PMID:
26134280
45.

Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.

Alfirevic A, Durocher J, Elati A, León W, Dickens D, Rädisch S, Box H, Siccardi M, Curley P, Xinarianos G, Ardeshana A, Owen A, Zhang JE, Pirmohamed M, Alfirevic Z, Weeks A, Winikoff B.

Pharmacogenomics. 2015;16(9):919-28. doi: 10.2217/pgs.15.53. Epub 2015 Jun 30.

PMID:
26122863
46.

Mifepristone label laws and trends in use: recent experiences in four US states.

Sheldon WR, Winikoff B.

Contraception. 2015 Sep;92(3):182-5. doi: 10.1016/j.contraception.2015.06.017. Epub 2015 Jun 23. No abstract available.

PMID:
26116033
47.

Continuing pregnancy after mifepristone and "reversal" of first-trimester medical abortion: a systematic review.

Grossman D, White K, Harris L, Reeves M, Blumenthal PD, Winikoff B, Grimes DA.

Contraception. 2015 Sep;92(3):206-11. doi: 10.1016/j.contraception.2015.06.001. Epub 2015 Jun 7. Review.

PMID:
26057457
48.

A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy.

Dabash R, Chelli H, Hajri S, Shochet T, Raghavan S, Winikoff B.

Int J Gynaecol Obstet. 2015 Jul;130(1):40-4. doi: 10.1016/j.ijgo.2015.02.023. Epub 2015 Apr 11.

PMID:
25896965
49.

Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City.

Sanhueza Smith P, Peña M, Dzuba IG, García Martinez ML, Aranguré Peraza AG, Bousiéguez M, Shochet T, Winikoff B.

Reprod Health Matters. 2015 Feb;22(44 Suppl 1):75-82. doi: 10.1016/S0968-8080(15)43825-X.

50.

The introduction of first trimester medical abortion in Armenia.

Louie KS, Chong E, Tsereteli T, Avagyan G, Vardanyan S, Winikoff B.

Reprod Health Matters. 2015 Feb;22(44 Suppl 1):56-66. doi: 10.1016/S0968-8080(15)43824-8.

Supplemental Content

Loading ...
Support Center